Astellas Pharma announces that the China National Medical Products Administration approved a NDA for XTANDI (enzalutamide) for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.